These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 19010207)

  • 21. Initial low-dose valganciclovir as a preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients.
    Takenaka K; Nagafuji K; Takase K; Kamimura T; Mori Y; Ito Y; Nishi Y; Henzan H; Kato K; Harada N; Eto T; Miyamoto T; Teshima T; Akashi K
    Int J Hematol; 2012 Jul; 96(1):94-100. PubMed ID: 22547196
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preemptive therapy with intravenous ganciclovir for the prevention of cytomegalovirus disease in lung transplant recipients.
    Monforte V; Román A; Gavaldà J; Bravo C; Gispert P; Pahissa A; Morell F
    Transplant Proc; 2005 Nov; 37(9):4039-42. PubMed ID: 16386621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients.
    Humar A; Lipton J; Welsh S; Moussa G; Messner H; Mazzulli T
    Bone Marrow Transplant; 2001 Sep; 28(5):485-90. PubMed ID: 11593322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients.
    Ruiz-Camps I; Len O; de la Cámara R; Gurguí M; Martino R; Jarque I; Barrenetxea C; Díaz de Heredia C; Batlle M; Rovira M; de la Torre J; Torres A; Aguilar M; Espigado I; Martín-Dávila P; Bou G; Borrell N; Aguado JM; Pahissa A;
    Antivir Ther; 2011; 16(7):951-7. PubMed ID: 22024510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral ganciclovir versus valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients.
    Brady RL; Green K; Frei C; Maxwell P
    Transpl Infect Dis; 2009 Apr; 11(2):106-11. PubMed ID: 19054381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients.
    Singh N
    Clin Infect Dis; 2001 Mar; 32(5):742-51. PubMed ID: 11229841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
    Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients.
    Takenaka K; Eto T; Nagafuji K; Kamezaki K; Matsuo Y; Yoshimoto G; Harada N; Yoshida M; Henzan H; Takase K; Miyamoto T; Akashi K; Harada M; Teshima T;
    Int J Hematol; 2009 Mar; 89(2):231-237. PubMed ID: 19148587
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance.
    van der Beek MT; Berger SP; Vossen AC; van der Blij-de Brouwer CS; Press RR; de Fijter JW; Claas EC; Kroes AC
    Transplantation; 2010 Feb; 89(3):320-6. PubMed ID: 20145523
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High efficacy and low toxicity of short-course oral valganciclovir as pre-emptive therapy for hematopoietic stem cell transplant cytomegalovirus infection.
    Saleh AJ; Al Mohareb F; Al Rabiah F; Chaudhri N; Al Sharif F; Al Zahrani H; Mohamed SY; Patel M; Rasheed W; Nurgat Z; Bakr M; Ahmed S; Zaidi S; Nasser A; Ibrahim K; Al Abdely H; Aljurf M
    Hematol Oncol Stem Cell Ther; 2010; 3(3):116-20. PubMed ID: 20890068
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation.
    Solano C; Muñoz I; Gutiérrez A; Farga A; Prósper F; García-Conde J; Navarro D; Gimeno C
    J Clin Microbiol; 2001 Nov; 39(11):3938-41. PubMed ID: 11682510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis.
    Shiley KT; Gasink LB; Barton TD; Pfeiffenberger P; Olthoff KM; Blumberg EA
    Liver Transpl; 2009 Aug; 15(8):963-7. PubMed ID: 19642123
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients.
    Kim JM; Kwon CH; Joh JW; Ha YE; Sinn DH; Choi GS; Peck KR; Lee SK
    PLoS One; 2015; 10(5):e0123554. PubMed ID: 25942443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Valganciclovir preemptive therapy for the prevention of cytomegalovirus disease in high-risk seropositive solid-organ transplant recipients.
    Díaz-Pedroche C; Lumbreras C; San Juan R; Folgueira D; Andrés A; Delgado J; Meneu JC; Morales JM; Moreno-Elola A; Hernando S; Moreno-González E; Aguado JM
    Transplantation; 2006 Jul; 82(1):30-5. PubMed ID: 16861938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract.
    Winston DJ; Baden LR; Gabriel DA; Emmanouilides C; Shaw LM; Lange WR; Ratanatharathorn V
    Biol Blood Marrow Transplant; 2006 Jun; 12(6):635-40. PubMed ID: 16737936
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost analysis in favor of a combined approach for cytomegalovirus after kidney transplantation: a single-center experience.
    Hellemans R; Beutels P; Ieven M; Verpooten GA; Bosmans JL
    Transpl Infect Dis; 2013 Feb; 15(1):70-8. PubMed ID: 23173691
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Utility of oral valganciclovir for cytomegalovirus prophylaxis: does it improve treatment compliance?
    Moro JA; Almenar L; Martínez-Dolz L; Blanes M; Agüero J; Sánchez-Lázaro I; Salvador A
    Transplant Proc; 2008 Nov; 40(9):3063-4. PubMed ID: 19010195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts.
    Singh N; Wannstedt C; Keyes L; Mayher D; Tickerhoof L; Akoad M; Wagener MM; Cacciarelli TV
    Liver Transpl; 2008 Feb; 14(2):240-4. PubMed ID: 18236404
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of CMV disease in allogeneic BMT recipients by cytomegalovirus antigenemia-guided preemptive ganciclovir therapy.
    Koehler M; St George K; Ehrlich GD; Mirro J; Neudorf SM; Rinaldo C
    J Pediatr Hematol Oncol; 1997; 19(1):43-7. PubMed ID: 9065718
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preemptive therapy for the prevention of cytomegalovirus disease in renal transplant recipients: our preliminary experience.
    Paudice N; Mehmetaj A; Zanazzi M; Moscarelli L; Piperno R; Di Maria L; Bertoni E; Salvadori M
    Transplant Proc; 2009 May; 41(4):1204-6. PubMed ID: 19460517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.